Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz2. fázis

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

A legfontosabb adatok

Ki végzi
Eagle Pharmaceuticals, Inc.
Hol
Chicago, Cleveland, Fresno, Gainesville, Galveston, Omaha és Winston-Salem (Egyesült Államok)Mind a 7 helyszín megnézéseMég 18 másik országban, 83 helyszínen
Azonosító
Állapot
Fut, nem toboroz
Fázis
2. fázis
Résztvevők
276 fő, tervezett
Kezdés
2023. júl. 22.
Befejezés
2026. szept. 7.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • CAL02
  • Placebo
A regiszteradat frissítve
2026. január 28.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 30 feltétel megnézéseKevesebb

Ki vehet részt

  • male or females older than 18 years old
  • Body Weight 40 - 140 kg
  • clinical diagnosis of CABP diagnosed less than or equal to 48 hrs after hospital admission
  • presence of at least one of the protocol defined SCABP severity criteria:
  • at least two clinical symptoms
  • at least 2 vital sign abnormalities
  • at least one finding of other clinical signs/laboratory abnormalities
  • radiographic evidence in support of pneumonia with likely bacterial origin
  • presence of at least one of the following severity criteria based on protocol defined SCABP:
  • respiratory failure requiring invasive mechanical ventilation support
  • respiratory failure requiring non-invasive positive pressure ventilation support
  • respiratory failure requiring high-flow oxygen
  • septic shock requiring treatment with vasopressors at therapeutic doses for at least 2 hours
  • requires critical care for management of SCABP
  • onset of severity criteria less than 48 hours from diagnosis of CABP or upon discussion with medical monitor
  • written informed consent before any study-specific assessment is performed

Ki nem vehet részt

  • subject received IV antibiotics for CABP/SCABP for more than 48 hours at the time of randomization if sensitivity supports appropriate empiric therapy chosen and administered
  • renal replacement therapy
  • known hypersensitivity to liposomal formulations
  • end-stage neuromuscular disorders, tracheostomy, known bronchial obstruction, post-operative aspiration pneumonia, cystic fibrosis, known or suspected pneumocystis jirovecii or tuberculosis pneumonia, post organ transplant, or primary or metastatic malignancy in the lungs
  • known liver dysfunction, chronic liver disease with Child Pugh C or esophageal varices
  • moribund clinical conditions at the time of screening or time of the first study medication infusion
  • subject has any medical disease or condition that, in the opinion of the investigator, compromises the subject's safety or compromises the interpretation of results
  • subjects with ventilator-associated pneumonia, aspiration pneumonia, fungal pneumonia, viral pneumonia (viral coinfection may be exempted subject to discussion with medical monitor)
  • subjects more than 12 hours from the diagnosis of SCABP
  • SOFA score greater than 12 points
  • current or recent participation in an investigational study (within 30 days of screening or 5 half-lives of the investigational compound, whichever is longer)
  • refractory septic shock at the time of randomization
  • nursing and pregnant women
  • women of childbearing potential and non-surgically sterile males

Helyszínek itt: Egyesült Államok

Még 18 másik országban, 83 helyszínen

  • Northwestern Memorial HospitalChicago, Egyesült Államok
  • Cleveland Clinic Fairview HospitalCleveland, Egyesült Államok
  • UCSF HospitalFresno, Egyesült Államok
  • UF Health Shands HospitalGainesville, Egyesült Államok
  • University of Texas Medical BranchGalveston, Egyesült Államok
  • University of Nebraska Medical CenterOmaha, Egyesült Államok
  • Wake Forest Baptist Health HospitalWinston-Salem, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures

A vizsgálat 2 csoportja

  • CAL02 with Standard of CareA vizsgált kezelés

    CAL02 (a mixture of 2 liposomal components, both empty, unilamellar, liposomes) will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. CAL02 infusions will be administered over a 1 -2 hour period.

    Kezelés: CAL02

  • PlaceboPlacebo, összehasonlításként

    Placebo will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. Placebo will be prepared and administered following the same infusion protocol as CAL02. Placebo infusions will be administered over a 1 to 2 hour period.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)
A regiszteradat frissítve
2026. január 28.